Preliminary Studies of the Prevalence and Possible Clinical Consequences of Potential Simple and Multifactorial Drug and Gene Interactions of Anti-depressants in Older Australians

Abstract

Event Abstract Back to Event Preliminary Studies of the Prevalence and Possible Clinical Consequences of Potential Simple and Multifactorial Drug and Gene Interactions of Anti-depressants in Older Australians Mohitosh Biswas1*, Thilani H Dias2, Elizabeth Holliday2, Stephen Hancock2, John Attia2, Rodney J. Scott2, David Newby2, Karen P Kerr2 and Liz Milward2 1 University of Rajshahi, Bangladesh 2 University of Newcastle, Australia Introduction Antidepressant drugs are often prescribed to treat psychiatric disorders in cancer patients. The safety or efficacy of these drugs may be affected by clinically significant drug-drug interactions (DDIs), drug gene interactions (DGIs) or combinations of these (multifactorial DGIs). The present study aimed to determine the prevalence of potential simple or multifactorial DGIs of participants taking antidepressant drugs of interest (TCAs or SSRIs) in older Australians where polypharmacy is common. Methods Co-prescribed interacting medications were identified from self-reported medication data of 2,642 participants aged over 55 in the Australian Hunter community study. Predicted drug and gene interactions were identified from genotyping data using Affymetrix Kaiser Axiom arrays and imputed data from the 1000 Genomes and HapMap Phase II European reference panels.Clinically significant pharmacogenotypes were identified from Clinical Pharmacogenetics Implementation Consortium (CPIC) pharmacogenomics based dosing guidelines. Results Of the 270 participants on antidepressant drugs of interest (TCAs or SSRIs), 174 (64.4%; 95% CI 59%-70%) were co-prescribed at least one potential clinically significant interacting drug, with a mean of 1.6±0.8 possible interactions per participant. Genotype data were available for 128 of the 270 participants taking antidepressant drugs, with 15 participants (11.7%; 95% CI 6%-17%) identified as being at risk of clinically significant simple DGIs and 20 participants (15.6%; 95% CI 9%-22%) at risk of clinically significant multifactorial DGIs. These findings suggest a considerable proportion of participants using TCAs or SSRIs are at risk of drug and gene interactions affecting the safety or efficacy of these drugs. Discussion Over 1/4 participants on antidepressants may be at increased risk of adverse reactions involving drug-gene interactions that may justify dose adjustment. This emphasizes the potential value of considering the pharmacogenomics of antidepressants in conjunction with drug interaction analyses.This should be taken into consideration when applying precision medicine approaches to improve outcomes in cancer patients. Keywords: psychiatric disorders, Antidepressants, DDI, pharmacogenomics, precision medicine Conference: International Conference on Drug Discovery and Translational Medicine 2018 (ICDDTM '18) “Seizing Opportunities and Addressing Challenges of Precision Medicine”, Putrajaya, Malaysia, 3 Dec - 5 Feb, 2019. Presentation Type: Oral Presentation Topic: Neurodegenerative diseases Citation: Biswas M, Dias T, Holliday E, Hancock S, Attia J, Scott RJ, Newby D, Kerr K and Milward L (2019). Preliminary Studies of the Prevalence and Possible Clinical Consequences of Potential Simple and Multifactorial Drug and Gene Interactions of Anti-depressants in Older Australians. Front. Pharmacol. Conference Abstract: International Conference on Drug Discovery and Translational Medicine 2018 (ICDDTM '18) “Seizing Opportunities and Addressing Challenges of Precision Medicine”. doi: 10.3389/conf.fphar.2018.63.00021 Copyright: The abstracts in this collection have not been subject to any Frontiers peer review or checks, and are not endorsed by Frontiers. They are made available through the Frontiers publishing platform as a service to conference organizers and presenters. The copyright in the individual abstracts is owned by the author of each abstract or his/her employer unless otherwise stated. Each abstract, as well as the collection of abstracts, are published under a Creative Commons CC-BY 4.0 (attribution) licence (https://creativecommons.org/licenses/by/4.0/) and may thus be reproduced, translated, adapted and be the subject of derivative works provided the authors and Frontiers are attributed. For Frontiers’ terms and conditions please see https://www.frontiersin.org/legal/terms-and-conditions. Received: 15 Nov 2018; Published Online: 17 Jan 2019. * Correspondence: Dr. Mohitosh Biswas, University of Rajshahi, Rajshahi, Bangladesh, biswas_07pharm@ru.ac.bd Login Required This action requires you to be registered with Frontiers and logged in. To register or login click here. Abstract Info Abstract The Authors in Frontiers Mohitosh Biswas Thilani H Dias Elizabeth Holliday Stephen Hancock John Attia Rodney J Scott David Newby Karen P Kerr Liz Milward Google Mohitosh Biswas Thilani H Dias Elizabeth Holliday Stephen Hancock John Attia Rodney J Scott David Newby Karen P Kerr Liz Milward Google Scholar Mohitosh Biswas Thilani H Dias Elizabeth Holliday Stephen Hancock John Attia Rodney J Scott David Newby Karen P Kerr Liz Milward PubMed Mohitosh Biswas Thilani H Dias Elizabeth Holliday Stephen Hancock John Attia Rodney J Scott David Newby Karen P Kerr Liz Milward Related Article in Frontiers Google Scholar PubMed Abstract Close Back to top Javascript is disabled. Please enable Javascript in your browser settings in order to see all the content on this page.